Acupuncture for Postherpetic Neuralgia: Meta-Analysis Points to Reduced Pain Intensity in Combination with Pharmacologic Treatment

Postherpetic neuralgia (PHN) is defined as neuropathic pain that persists for more than 90 days after the onset of the herpes zoster rash, occurring in 10% to 20% of patients — most frequently in those over age 60. The condition can be severely disabling, with burning pain, tactile allodynia, and persistent dysesthesias. First-line pharmacologic treatments include gabapentinoids (gabapentin, pregabalin), tricyclic antidepressants (amitriptyline, nortriptyline), and the lidocaine 5% patch. Vaccination against herpes zoster (Shingrix) is the most effective prevention strategy, but for patients with established PHN, adjuvant options — including acupuncture — remain under investigation.

What the Literature Shows

Meta-analyses suggest a modest to moderate reduction in pain intensity compared with pharmacologic treatment alone, with effect magnitude smaller than that observed in other neuropathic pain conditions. There are signs of additional benefit on multidimensional scales (NPSI, SF-MPQ) and on quality of life. The combination of segmental acupuncture (with points on the affected dermatome) and cupping appears to offer better response than either modality alone.

Mechanistic Plausibility

PHN involves both peripheral changes (axonal loss, denervated fibers, peripheral sensitization) and central changes (central sensitization, alterations in the spinal dorsal horn and supraspinal pathways). Segmental acupuncture may act via gate control, descending modulation through the PAG and RVM, reduction of central sensitization, and attenuation of local inflammatory markers. Electroacupuncture at mixed frequencies shows greater activation of these pathways than manual acupuncture alone in animal models.

Limitations of the Evidence

The literature is dominated by Asian studies with moderate sample size and limited blinding. Diagnostic criteria for PHN vary, and PHN duration before treatment differs across studies. Pragmatic Western trials and data on dose reduction of gabapentinoids or antidepressants with adjuvant acupuncture are lacking.